Prevention and Control of Infections in Patients with Severe Congenital Neutropenia; A Follow up Study

Severe Congenital Neutropenia is one of primary immunodeficiency disorders that characterized by severe neutropenia and is associated with severe systemic bacterial infections from early infancy. Granulocyte Colony Stimulating Factor (GCSF) is clinically used as a treatment for congenital and acquired neutropenia. The aim of this study was evaluation of GCSF (PD- Grastim) in treatment of these patients.
Patients with severe congenital neutropenia referred to Immunology, Asthma and Allergy Research Institute between Jan 2007 and Dec 2010 enrolled the study. Other causes of neutropenia were excluded by serial CBC and bone marrow studies, medical and drug histories and immunological tests. Patients were visited and examined monthly to evaluate their CBC and ANC (Absolute Neutrophil Count), GCSF side effects and dosage adjustment. Cytogenetic studies were being done for all the patients for early detection of progression to AML/MDS.
From twenty two patients who enrolled this study, 16 patients regularly evaluated. They were ten males and six females, range in age from 2 to 18 years old. Two patients failed to continue our follow up unfortunately and four patients died due to disease complications. Patients were followed for 24 to 48 months. In a period of 12-24 months before treatment, the mean of hospitalization frequency was 3.1 times and duration was 10 days; while during receiving treatment, they decreased to 0.2 times and 3 days, respectively (p<0.01). Also significant increase in mean ANC was observed during follow up (315/µl before treatment versus 1749/µl after 12 month regular treatment). Bone pain was the most common side effect.
There have been no evidences of developing AML/MDS up to present time. Treatment with GCSF significantly reduced the duration and the frequency of hospitalization. Because of plausible progression to AML/MDS, regular follow-up of patients should be continued.

1. Welte K, Zeidler C. Severe congenital neutropenia.Hematol Oncol Clin North Am 2009; 23(2):307-20.
2. Klein C, Welte K. Genetic Insights intoCongenital Neutropenia. Clin Rev Allerg Immunol 2010;38(1):68–7.
3. Ward AC, Dale DC. Genetic and molecular diagnosis of severe congenital neutropenia. Curr Opin Hematol 2009;16(1):9-13.
4. Liongue C, Wright C, Russell AP, Ward AC. Granulocyte colony-stimulating factor receptor: Stimulating granulopoiesis and much more. Int J Biochem Cell Biol 2009; 41(12):2372-5.
5. Leung TF, Li CK, Kwok KL, Chik KW, Shing MM, Yuen PM. Severe chronic neutropenia in Chinese children in Hong Kong J Paediatr Child Health 2001; 37(2):137-41.
6. Dale DC, Cottle TE, Fier CJ, Bolyard AA, Bonilla MA, Boxer LA, et al. Severe Chronic Neutropenia: Treatment and Follow-Upof Patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 2003;72(2):82-93.
7. James RM, SE Kinsey. The investigation and management of chronic neutropenia in children.Arch Dis Child 2006;91(10):852–8.
8. Cottle TE, Fier CJ, Donadieu J, Kinsey SE. Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor. Semin hematol 2002; 39(2):134-40.
9. Niemeyer CM, Kratz CP. Is granulocyte colony- stimulating factor therapy a risk factor for myelodysplasia/leukemia in patients with congenital neutropenia? Haematologica 2005; 90(1):2-3.
10. Ancliff PJ, Gale RE, Liesner R, Hann I, Linch DC. Long- term follow-up of granulocyte colony-stimulating factor receptor mutations in patients with severe congenital neutropenia: implications for leukaemogenesis and therapy. Br J Haematol 2003; 120(4):685-90.
11. Zeidler C, Germeshausen M, Klein C, Welte K. Clinical implications of ELA2-, HAX1-, and G-CSF- receptor(CSF3R) mutations in severe congenital neutropenia. Br J Haematol 2009; 144(4):459-67.
12. Zeidler C, Welte K, Barak Y, Barriga F, Bolyard AA, Boxer L, et al. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation. Blood 2000; 95(4):1195-8.
13. Badolato R, Fontana S, Notarangelo LD, Savoldi G.Congenital neutropenia: advances in diagnosis and treatment. Curr Opin Allergy Clin Immunol 2004;4(6):513-21.
14. Rezaei N, Moin M, Pourpak Z, Ramyar A, Izadyar M, Chavoshzadeh Z. The Clinical, Immunohematological, and Molecular Study of Iranian Patients with Severe Congenital Neutropenia. J Clin Immunol 2007; 27(5):525–33.
15. Rezaei N, Farhoudi A, Pourpak Z, Aghamohammadi A, Ramyar A, Moin M, et al. Clinical and Laboratory Findings in Iranian Children with Cyclic Neutropenia. Iran J Allergy Asthma Immunol 2004; 3(1):37-40.
16. Boztug K, Welte K, Zeidler C, Klein C. Congenital Neutropenia Syndromes. Immunol Allergy Clin North Am 2008; 28(2):259-75.
17. Beaupain B, Leblanc T, Reman O, Hermine O, Vannier JP, Suarez F, et al. Is Pegfilgrastim Safe and Effective in Congenital Neutropenia? An Analysisof the French Severe Chronic Neutropenia Registry. Pediatr Blood Cancer 2009;53(6):1068–73.
18. Shannon K. Reconsidering how we treat severe congenital neutropenia. Blood 2006; 107(12):4575-6.
19. Donadieu J, Boutard P, Bernatowska E, Tchernia G, Couillaud G, Philippe N, et al. A European phase II study of recombinant human granulocyte colony-stimulating factor (lenograstim) in the treatment of severe chronic neutropenia in children. Lenograstim Study Group. Eur J Pediatr 1997; 156(9):693-700.
20. Calderwood S, Kilpatrick L, Douglas SD, Fredddman M, Smith-Whitely K, et al. Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b. Blood 2001; 97(2):376-82.
21. Sotomatsu M, Kanazawa T, Ogawa C, Watanabe T, Morikawa A. Complication of rapidly progressive glomerulonephritis in severe congenital neutropenia treated with long-term granulocyte colony-stimulating factor (filgrastim). Br J Haematol 2000; 110(1):234–5.
22. Alizadeh Z, Fazllollahi M, Eshghi P, Hamidieh A, Ghadami M, Pourpak Z. Two cases of syndromic neutropenia with a report of novel mutation in G6PC3. Iran J Allergy Asthma Immunol 2011; 10(3):227-30.
23. Dale DC. Recent progress in understanding the congenital neutropenia. Curr Opin Hematol 2010; 17(1):1-2.
24. Rosenberg PS, Alter BP, Link DC, Stein S, Rodger E, Bolyard AA, et al. Neutrophil elastase mutations and risk of leukemia in severe congenital neutropenia. Br J Haematol 2008; 140(2):210-3.

Files	XML PDF (264KB)
Issue	Vol 11, No 1 (2012)
Section	Articles
Keywords
GCSF Immunodeficiency Neutropenia Severe Congenital Neutropenia

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Salehi T, Fazlollahi MR, Maddah M, Nayebpour M, Tabatabaei Yazdi M, Alizadeh Z, Eshghi P, Chavoshzadeh Z, Movahedi M, Hamidieh AA, Cheraghi T, Pourpak Z, Moin M. Prevention and Control of Infections in Patients with Severe Congenital Neutropenia; A Follow up Study. Iran J Allergy Asthma Immunol. 1;11(1):51-56.

Vancouver

Download Citation